| EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
Breast
cancer
THE BENEFITS OF SEQUENCING ADJUVANT TAMOXIFEN AND ANASTROZOLE
IN POSTMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST
CANCER: 5 YEAR-ANALYSIS OF ABCSG TRIAL 8. SABCS 2005 ABSTRACT
13.
SWITCHING FROM ADJUVANT TAMOXIFEN TO
ANASTROZOLE IN POSTMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE
EARLY BREAST CANCER: A META-ANALYSIS OF THE ARNO 95 TRIAL,
ABCSG TRIAL 8, AND THE ITA TRIAL. SABCS 2005 ABSTRACT 18.
UPDATED ANALYSIS OF NCIC CTG MA.17 (LETROZOLE
VS. PLACEBO TO LETROZOLE VS PLACEBO) POST UNBLINDING. SABCS
2005 ABSTRACT 16.
ANALYSIS OF DURATION OF LETROZOLE EXTENDED
ADJUVANT THERAPY AS MEASURED BY HAZARD RATIOS OF DISEASE RECURRENCE
OVER TIME FOR PATIENTS ON NCIC CTG MA.17. SABCS 2005 ABSTRACT
17.
Myeloproliferative
syndromes
QUANTITATIVE ANALYSIS OF WILD TYPE AND V617F JAK-2 EXPRESSION
IN NEUTROPHILS OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
PATIENTS AT DIAGNOSIS. ASH 2005 ABSTRACT 257.
Multiple
myeloma
DOUBLE AUTOLOGOUS TRANSPLANT VERSUS TANDEM AUTOLOGUS —
NON MYELOABLATIVE ALLOGENEIC TRANSPLANT FOR NEWLY DIAGNOSED
MULTIPLE MYELOMA. ASH 2005 ABSTRACT 46.
NONMYELOABLATIVE UNRELATED DONOR (URD)
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR THE TREATMENT
OF PATIENTS (PTS) WITH POOR-RISK, RELAPSED OR REFRACTORY MULTIPLE
MYELOMA. ASH 2005 ABSTRACT 2893.
Diffuse
large B cell lymphoma
SIX, NOT EIGHT CYCLES OF BI-WEEKLY CHOP WITH RITUXIMAB (R-CHOP-14)
IS THE PREFERRED TREATMENT FOR ELDERLY PATIENTS WITH DLBCL:
RESULTS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN
LYMPHOMA STUDY GROUP (DSHNHL). ASH 2005 ABSTRACT 13.
| 
